Whole blood: Transport 5 mL whole blood. (Min: 3 mL) Bone marrow: Transport 3 mL bone marrow. (Min: 1 mL) Refrigerate immediately. Specimens must be received within 48 hours of collection due to lability of RNA.
Storage/Transport Temperature
Refrigerated.
Unacceptable Conditions
Serum, plasma, extracted DNA, CSF, FFPE tissue, ambient whole blood, or frozen whole blood or bone marrow. Specimens collected in anticoagulants other than EDTA. Severely hemolyzed or clotted specimens. Ambient bone marrow specimens past 7 days will be canceled. Refrigerated whole blood or bone marrow specimens past 7 days will be canceled.
This qualitative screening test is appropriate for initial diagnosis of chronic myeloid leukemia (CML) or acute lymphoblastic leukemia/lymphoma (ALL). Use to detect the presence of p210 (major breakpoint), p190 (minor breakpoint), and p230 (micro breakpoint) fusions. If a common p210 or p190 BCR::ABL1 fusion transcript is detected, the appropriate test will be added to provide a quantitative value, which may be used as the diagnostic baseline to further monitor treatment response.For patients with a known history of p210 or p190 fusion transcripts, refer to Quantitative Detection of BCR::ABL1, Major Form (p210) (3005840) or Quantitative Detection of BCR::ABL1, Minor Form (p190) (3016968). These two tests are the appropriate tests to monitor therapeutic response and to detect minimal residual disease (MRD). Low-level residual disease might not be detected by inappropriate use of this screening/diagnostic assay.
This reflex assay is recommended when the BCR::ABL1 fusion form is not known or unclear. This reflex assay detects the presence of either the p210 (major breakpoint), p190 (minor breakpoint), or p230 (micro breakpoint). If the presence of either the common p210 or p190 BCR::ABL1 fusion is detected, then the appropriate quantitative test will be performed. Additional charges apply.
If the fusion form is known, refer to Quantitative Detection of BCR::ABL1, Major Form (p210) (ARUP test code 3005840) or Quantitative Detection of BCR::ABL1, Minor Form (p190) (ARUP test code 3016968).
Remarks
This qualitative screening test is appropriate for initial diagnosis of chronic myeloid leukemia (CML) or acute lymphoblastic leukemia/lymphoma (ALL).
For patients with a known history of p210 or p190 fusion transcripts, refer to Quantitative Detection of BCR::ABL1, Major Form (p210) (ARUP test code 3005840) or Quantitative Detection of BCR::ABL1, Minor Form (p190) (ARUP test code 3016968).
Interpretive Data
Refer to report.
CPT Codes
81206; 81207; 81208; If reflexed, add 81206 or 81207
LOINC
31208-2
21821-4
Performing Lab
ARUP Laboratories
Collection
Department
Sendouts: ARUP 3005839 11/14/2022
Collect
Whole blood or bone marrow in lavender (EDTA).
Specimen Preparation
Whole blood: Transport 5 mL whole blood. (Min: 3 mL) Bone marrow: Transport 3 mL bone marrow. (Min: 1 mL) Refrigerate immediately. Specimens must be received within 48 hours of collection due to lability of RNA.
Storage/Transport Temperature
Refrigerated.
Unacceptable Conditions
Serum, plasma, extracted DNA, CSF, FFPE tissue, ambient whole blood, or frozen whole blood or bone marrow. Specimens collected in anticoagulants other than EDTA. Severely hemolyzed or clotted specimens. Ambient bone marrow specimens past 7 days will be canceled. Refrigerated whole blood or bone marrow specimens past 7 days will be canceled.
This qualitative screening test is appropriate for initial diagnosis of chronic myeloid leukemia (CML) or acute lymphoblastic leukemia/lymphoma (ALL). Use to detect the presence of p210 (major breakpoint), p190 (minor breakpoint), and p230 (micro breakpoint) fusions. If a common p210 or p190 BCR::ABL1 fusion transcript is detected, the appropriate test will be added to provide a quantitative value, which may be used as the diagnostic baseline to further monitor treatment response.For patients with a known history of p210 or p190 fusion transcripts, refer to Quantitative Detection of BCR::ABL1, Major Form (p210) (3005840) or Quantitative Detection of BCR::ABL1, Minor Form (p190) (3016968). These two tests are the appropriate tests to monitor therapeutic response and to detect minimal residual disease (MRD). Low-level residual disease might not be detected by inappropriate use of this screening/diagnostic assay.
This reflex assay is recommended when the BCR::ABL1 fusion form is not known or unclear. This reflex assay detects the presence of either the p210 (major breakpoint), p190 (minor breakpoint), or p230 (micro breakpoint). If the presence of either the common p210 or p190 BCR::ABL1 fusion is detected, then the appropriate quantitative test will be performed. Additional charges apply.
If the fusion form is known, refer to Quantitative Detection of BCR::ABL1, Major Form (p210) (ARUP test code 3005840) or Quantitative Detection of BCR::ABL1, Minor Form (p190) (ARUP test code 3016968).
Remarks
This qualitative screening test is appropriate for initial diagnosis of chronic myeloid leukemia (CML) or acute lymphoblastic leukemia/lymphoma (ALL).
For patients with a known history of p210 or p190 fusion transcripts, refer to Quantitative Detection of BCR::ABL1, Major Form (p210) (ARUP test code 3005840) or Quantitative Detection of BCR::ABL1, Minor Form (p190) (ARUP test code 3016968).
Result Interpretation
Interpretive Data
Refer to report.
Administrative
CPT Codes
81206; 81207; 81208; If reflexed, add 81206 or 81207
Laboratories.